Xin Zhai

846 total citations
66 papers, 695 citations indexed

About

Xin Zhai is a scholar working on Molecular Biology, Organic Chemistry and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xin Zhai has authored 66 papers receiving a total of 695 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Molecular Biology, 32 papers in Organic Chemistry and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xin Zhai's work include Synthesis and biological activity (22 papers), Cancer therapeutics and mechanisms (20 papers) and Lung Cancer Treatments and Mutations (17 papers). Xin Zhai is often cited by papers focused on Synthesis and biological activity (22 papers), Cancer therapeutics and mechanisms (20 papers) and Lung Cancer Treatments and Mutations (17 papers). Xin Zhai collaborates with scholars based in China and Singapore. Xin Zhai's co-authors include Ping Gong, Ming Guo, Daiying Zuo, Nan Jiang, Junjie Ma, Yanfang Zhao, Wufu Zhu, Wenfeng Gou, Lijun Xie and Tianming Zhao and has published in prestigious journals such as Science Advances, Molecules and Cancer Letters.

In The Last Decade

Xin Zhai

65 papers receiving 690 citations

Peers

Countries citing papers authored by Xin Zhai

Since Specialization

Citations

This map shows the geographic impact of Xin Zhai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xin Zhai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xin Zhai more than expected).

Fields of papers citing papers by Xin Zhai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xin Zhai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xin Zhai. The network helps show where Xin Zhai may publish in the future.

Co-authorship network of co-authors of Xin Zhai

This figure shows the co-authorship network connecting the top 25 collaborators of Xin Zhai. A scholar is included among the top collaborators of Xin Zhai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xin Zhai. Xin Zhai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Rational design and identification of potent imidazole-fused Autotaxin inhibitors for treatment of idiopathic pulmonary fibrosis	European Journal of Medicinal Chemistry	Bing Zhao, You Li et al.	0
2	Rational design and synthesis of 6-(piperazin-1-yl)imidazo[1,2-b]pyridazine derivatives as dual FXR/PPARδ agonists for treatment of pulmonary fibrosis	European Journal of Medicinal Chemistry	Nan Jiang, Ren Yi et al.	1
3	Research progress on covalent inhibitors targeting alkaline amino acids	Bioorganic Chemistry	Bing Zhao, Sha Xu et al.	1
4	Development of potent indole-3-carboxamide autotaxin inhibitors with preferred lipophilicity for in vivo treatment of pulmonary fibrosis	European Journal of Medicinal Chemistry	Deyi Ma, Nan Jiang et al.	1
5	Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment	European Journal of Medicinal Chemistry	Bing Zhao, Nan Jiang et al.	11
6	Discovery of first-in-class DOT1L inhibitors against the R231Q gain-of-function mutation in the catalytic domain with therapeutic potential of lung cancer	Acta Pharmaceutica Sinica B	Zhi Cao, Shuyu Liu et al.	3
7	Gain-of-function mutations in the catalytic domain of DOT1L promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway	Science Advances	Mei Han, Xiaoxuan Wang et al.	12
8	Development of a new type of multi-functional mechanochromic luminescence material by infusing a phenyl rotator into the structure of 3,4-diphenylmaleic anhydride	New Journal of Chemistry	Zexin Wang, Liwei Chen et al.	2
9	Design, synthesis and anti-tumor efficacy of novel phenyl thiazole/triazole derivatives as selective TrkA inhibitors	Bioorganic & Medicinal Chemistry	Xinyu Wang, Fuyi Wang et al.	1
10	Design, synthesis and antitumor evaluation of ATP dual-mimic 2,4-diarylaminopyrimidine and aminoindazole conjugates as potent anaplastic lymphoma kinase inhibitors	European Journal of Medicinal Chemistry	Jing Yang, Deyi Ma et al.	3
11	Harmine-inspired design and synthesis of benzo[d]imidazo[2,1-b]thiazole derivatives bearing 1,3,4-oxadiazole moiety as potential tumor suppressors	Bioorganic & Medicinal Chemistry	Tianming Zhao, Yang Yu et al.	14
12	Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects	Bioorganic & Medicinal Chemistry	Zheng Li, Ming Guo et al.	7
13	Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model	European Journal of Medicinal Chemistry	Zhi Cao, Tong Li et al.	9
14	Nucleoside and Non-Nucleoside DOT1L Inhibitors: Dawn of MLLrearranged Leukemia	Mini-Reviews in Medicinal Chemistry	Tong Li, Yuxiang Chen et al.	5
15	Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants	Bioorganic & Medicinal Chemistry	Wei Li, Tianming Zhao et al.	10
16	CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib	Cancer Letters	Wenfeng Gou, Xuejiao Zhou et al.	46
17	Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives	European Journal of Medicinal Chemistry	Ming Guo, Daiying Zuo et al.	24
18	5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells	Chemico-Biological Interactions	Mengting Han, Lijing Wang et al.	9
19	Synthesis, biological evaluation and molecular modeling of imidazo[1,2-a]pyridine derivatives as potent antitubulin agents	Bioorganic & Medicinal Chemistry	Daiying Zuo, Ming Guo et al.	16
20	Design, Synthesis and Evaluation of Novel Rhodanine‐containing Sorafenib Analogs as Potential Antitumor Agents	Archiv der Pharmazie	Wei Li, Xin Zhai et al.	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact